title: Lamellar macular hole after intravitreal ocriplasmin injection.
abstract: Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.
authors.affiliation: Department of Ophthalmology, St Louis University Eye Institute, St Louis, Missouri, USA.
authors.forename: Ross Bronson
authors.initials: RB
authors.lastname: Chod
authors.affiliation: Department of Ophthalmology, St Louis University Eye Institute, St Louis, Missouri, USA.
authors.forename: Clifford
authors.initials: C
authors.lastname: Goodrich
authors.affiliation: Department of Ophthalmology, CSM Medical University, Lucknow, Uttar Pradesh, India.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Saxena
authors.affiliation: Department of Ophthalmology, St Louis University Eye Institute, St Louis, Missouri, USA.
authors.forename: Levent
authors.initials: L
authors.lastname: Akduman
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D058449:Intravitreal Injections; D008266:Macula Lutea / Q000187:drug effects*; D010446:Peptide Fragments / Q000008:administration & dosage* / Q000009:adverse effects*; D012167:Retinal Perforations / Q000139:chemically induced* / Q000188:drug therapy; D000267:Tissue Adhesions / Q000188:drug therapy; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin